World’s top-selling drug going off patent means big bucks for middlemen
2 min read . Updated: 05 Dec 2022, 01:16 PM IST
PremiumAs AbbVie’s Humira faces copycat biologics, the biggest beneficiaries will be the middlemen.
Starting next year the highest-grossing drug of all time, AbbVie‘s Humira, will finally face competition from copycat biologics in the U.S.
×![]()
